L
iving kidney donation is the gold standard treatment of end-stage renal disease (ESRD); more than 8000 living-donor kidney transplantations were done in 2013 in the United States, Brazil, and Japan alone (1) . Although living donation is highly beneficial to recipients, it remains a complex ethical, moral, and medical issue. It is practiced with the expectation that risk for minimal short-and long-term harm to the donor is outweighed by the psychological benefits of altruism and improved recipient health (2) . A short-term reduction in glomerular filtration rate after nephrectomy is a known consequence of kidney donation (3) . However, the midand long-term health risks remain uncertain, despite their critical role in informing clinical guidelines for follow-up and supporting the process of informed consent (4, 5) .
Although narrative reviews (1, 6, 7) and individual studies have reported on the longer-term health risks of living kidney donation, most have not been systematically assessed and quantified. For example, the 3 previously published meta-analyses (each involving up to 6 studies comparing donors vs. a nondonor control group) focused only on a limited number of outcomes (such as hypertension and renal function) and involved only about half of the currently available data (3, 8, 9) . Interpretation of the evidence has also been complicated by diverse selection criteria for nondonor control groups (for example, general population vs. based on donation criteria), follow-up durations, and analytic approaches (for example, different matching criteria or adjustment for potential confounders) (4, 10) .
To help quantify the mid-and long-term risks of living kidney donation, we conducted a systematic review and meta-analysis of observational studies comparing living kidney donors with control participants (nondonors) for a broad range of health outcomes.
supplemented this search by scanning reference lists of relevant articles (including studies as well as reviews and meta-analyses) and by backward and forward citation searching of all included studies. The computerbased searches combined terms related to "living organ donation," "health related quality of life," and "epidemiological studies" without health outcomes restriction (Supplement, available at Annals.org).
Study Selection
Studies were eligible for inclusion if they reported associations between living kidney donation and any health outcomes, disease traits, or health-related quality of life (HRQoL) using a validated instrument; had a mean follow-up after donation of at least 1 year; and provided a comparison group of control participants who had not donated a kidney. Outcomes evaluated in only 1 study (gout and kidney stones) were not included.
Data Extraction and Quality Assessment
Two investigators independently extracted data on the following characteristics using standardized protocols: sample size; study design; sampling population; location; year of publication; years of baseline survey (year of kidney donation); follow-up duration; participant sex, age range, and ethnicity; number of donors and control participants; selection criteria for control participants; outcomes recorded; outcome definitions and methods of ascertainment (Supplement Table 1 , available at Annals.org); reported risk estimates; and degree of statistical adjustment used or, where relevant, mean level of disease traits and HRQoL assessment scores in donors and control participants. Discrepancies were resolved by discussion and adjudication by a third reviewer. We used the most up-todate or comprehensive information when more than 1 article reported on the same study.
Study quality was evaluated with the NewcastleOttawa Scale (NOS) (11) , which uses a "star" system (maximum of 9 stars) to assess quality in the following 3 domains: selection of participants, comparability of study groups, and ascertainment of outcomes of interest. Studies with 4 stars or more were rated as medium or higher quality. We classified selection of control participants as +++ if they were eligible for nephrectomy based on medical status and assessment of renal function; ++ if they were eligible for nephrectomy based on medical status but without assessment of renal function, or if renal function was assessed but limited information on medical history was available; and + if limited screening or information on controls selection was available. Furthermore, we classified matching of donors with control participants as +++ if it was done according to age, sex, sociodemographic factors, or other factors potentially influencing the outcome of interest (for example, body mass index, blood pressure, medical history, and smoking history); ++ if it was based on age, sex, and sociodemographic factors; + if it was based only on age or sex; and null if no matching was done.
Data Synthesis and Analysis
Primary analyses involved only within-study comparisons to limit potential biases. We restricted primary analyses to studies with an NOS score of at least 4 and baseline recruitment period ending in or after 2000 to provide more reliable and contemporary summary estimates. Supplementary analyses involved all available studies.
We used reported relative risks (RRs) or unadjusted RRs or odds ratios calculated from study-specific data to quantify the association between living kidney donation and each of the binary outcomes of interest. Hazard ratios and odds ratios were assumed to approximate the same measure of RR. Incidence rates per 1000 person-years in donors were extracted from studies or calculated as the ratio of events in donors and control participants over the number of person-years at risk. This number in each group was extracted from each study or estimated by multiplying the mean (or median) years of follow-up by the number of donors and control participants. For pregnancy outcomes, incidence of adverse outcomes per 100 pregnancies was calculated by dividing the number of adverse events by the number of pregnancies. We assessed continuous outcomes (disease traits and HRQoL outcomes) by comparing mean differences in living kidney donors with those in control participants for each study. Standardized mean difference (SMD) was calculated within each study as the mean difference between cases and control participants divided by the pooled SD (12) . This estimate allows comparison among disparate outcome measures reported with different units.
Summary RRs, incidence rates, and SMDs comparing donors with control participants were calculated for each outcome by pooling the study-specific estimates using the random-effects profile likelihood metaanalysis method (13) . Consistency of findings across individual studies for outcomes reported in 3 or more studies was assessed by the I 2 statistic. Evidence of publication bias across studies was assessed for outcomes with more than 10 studies using funnel plots and the Egger test. All analyses were 2-sided, used a significance level of P < 0.05, and were done with Stata, version 14.2 (StataCorp).
Role of the Funding Source
None of the funding organizations were involved in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. cruited donors from hospitals and 11 from national or regional donor registries (2 studies did not report this information). The average follow-up ranged from 1 to 24 years, and 14 studies reported a mean or median follow-up of 10 years or more. Selection of the control population differed between studies, with 8 studies selecting control participants from population-based studies, 11 from the general population, 14 from siblings and other volunteers, and 19 from other sources. Twenty-seven studies used several characteristics to match the control and donor populations, and 17 excluded control participants with 2 or more contraindications for nephrectomy. Of these, only 5 selected the control population on the basis of completion of living donor screening or eligibility for nephrectomy based on medical status and renal function tests (Supplement Table 2 , available at Annals.org). Twenty-eight studies were judged to have an NOS score of at least 4 (Supplement Table 3 , available at Annals.org) and had a baseline recruitment period ending in or after 2000.
Association With Disease Traits
Twenty-six studies reported associations with disease traits, of which 17 reported information on blood pressure, 6 on metabolic markers, and 17 on markers of renal function (Appendix Table) . In the primary analysis (up to 8 studies, 1040 donors, and 1032 control participants), living kidney donors had higher mean diastolic blood pressure (SMD, 0.17 [95% CI, 0.03 to 0.34]) and lower levels of high-density lipoprotein cholesterol than control participants (SMD, Ϫ0.29 [CI, Ϫ0.52 to Ϫ0.11]). Donors also had poorer renal function than control participants, with a lower mean estimated glomerular filtration rate (SMD, Ϫ1.59 [CI, Ϫ1.86 to Ϫ0.33]) and higher mean level of serum creatinine (SMD, 1.02 [CI, 0.44 to 1.60]) ( Figure 2 and Supplement Table 4 , available at Annals.org). The primary analysis showed no important or statistically significant differences in systolic blood pressure or in levels of total cholesterol, lowdensity lipoprotein cholesterol, triglyceride, or glucose. Association With All-Cause Mortality, Chronic Diseases, and Pregnancy-Related Outcomes Six studies reported on associations with all-cause mortality, 19 on chronic diseases, and 2 on pregnancyrelated outcomes (Appendix Table) . Of those reporting on chronic diseases, 3 reported on cancer, 4 on cardiovascular disease, 6 on type 2 diabetes, 11 on hypertension, and 4 on ESRD. In the primary analyses (up to 12 studies, 112 574 donors, and 84 355 control participants, with average follow-up of 5 to 15 years), we found no evidence of increased risk for all-cause mortality, cancer, cardiovascular disease, type 2 diabetes, or hypertension in living kidney donors compared with control participants. Donors had higher risk for ESRD Table 5 , available at Annals.org), with an incidence rate of ESRD per 1000 person-years of 0.5 event (CI, 0.1 to 4.9 events) in donors and 0.1 event (CI, 0.0 to 0.6 event) in control participants (Supplement Table 5 ). Only 2 studies reported pregnancy-related outcomes; both satisfied inclusion criteria for the primary analysis. We found no evidence of a statistically significant increased risk in female donors for gestational hypertension, low birthweight, or preterm birth. Female living kidney donors had higher risk for preeclampsia (RR, 2.12 [CI, 1.06 to 4.27]) ( Figure 3) . The incidence rate of preeclampsia per 100 pregnancies was 5.9 events (CI, 2.9 to 8.9 events) in donors and 3.1 events (CI, 2.9 to 3.3 events) SMDs from studies with baseline recruitment ending after 2000 and a Newcastle-Ottawa Scale score ≥4 were pooled using the profile likelihood meta-analysis method. Heterogeneity statistics for outcomes reported in >2 studies were as follows: diastolic blood pressure, I 2 = 70% (95% CI, 41% to 85%); systolic blood pressure, I 2 = 77% (CI, 57% to 88%); triglycerides, I 2 = 87% (CI, 62% to 95%); total cholesterol, I 2 = 84% (CI, 61% to 94%); glucose, I 2 = 85% (CI, 67% to 93%); eGFR, I 2 = 90% (CI, 83% to 94%); serum creatinine, I 2 = 86% (CI, 69% to 94%). Pooled mean differences for each trait are in Supplement Table 4 (available at Annals.org). To convert triglyceride levels to mmol/L, multiply by 0.0113. To convert cholesterol levels to mmol/L, multiply by 0.0259. To convert glucose levels to mmol/L, multiply by 0.0555. To convert creatinine levels to μmol/L, multiply by 88.4. eGFR = estimated glomerular filtration rate; HDL = high-density lipoprotein; LDL = low-density lipoprotein; SMD = standardized mean difference.
in control participants (Supplement Table 5 ). We found no evidence of publication bias for outcomes reported in more than 10 studies (Supplement Figure 1 , available at Annals.org).
Association With HRQoL
Thirteen studies reported HRQoL in living kidney donors versus control participants. All used the standardized Short Form-36 or Short Form-12 Health Sur- Analysis was restricted to studies with a baseline recruitment ending after 2000 and a Newcastle-Ottawa Scale score ≥4. Risk estimates were pooled using the profile likelihood meta-analysis method. Heterogeneity statistics for outcomes reported in >2 studies were as follows: all-cause mortality, I 2 = 97% (95% CI, 94% to 98%); cancer, I 2 = 0% (CI, 0% to 90%); cardiovascular disease, I 2 = 26% (CI, 0% to 72%); diabetes, I 2 = 0% (CI, 0% to 79%); ESRD, I 2 = 73% (CI, 9% to 92%); hypertension, I 2 = 85% (CI, 66% to 93%). Pooled risk estimates for each outcome are in Supplement Table 5 (available at Annals.org). ESRD = end-stage renal disease; NA = not available. * Incidence rates per 1000 person-years were calculated as the ratio of events in donors and control participants divided by number of person-years at risk (person-years at risk for donors and controls were approximated by multiplying the mean [or median] years of follow-up by the number of donors or controls). For pregnancy-related outcomes, incidence rates are the proportion of adverse pregnancy outcomes per 100 pregnancies.
vey to measure psychosocial and physical health. In the primary analyses (up to 10 studies, 5263 donors, and 25 528 control participants), we found no important or statistically significant differences in the physical or mental component scores between donors and control participants. However, some evidence suggested a higher vitality score in donors than control participants (SMD, 0.20 [CI, 0.10 to 0.31]) (Table and Supplement Figure 2 , available at Annals.org).
Supplementary Analyses
Overall results were similar in supplementary analyses, including all studies regardless of NOS score and baseline year of recruitment, with the exception of a higher mean systolic blood pressure, higher mean levels of urinary protein and albumin, and higher risk for hypertension in living kidney donors than control participants (Supplement Figures 3 and 4 , available at Annals.org). Some evidence also suggested higher physical component scores and general health scores in donors compared with controls (Supplement Table 6 and Supplement Figure 5 , available at Annals.org). We found no evidence of publication bias for disease traits or chronic disease outcomes reported in more than 10 studies (Supplement Figure 1 , available at Annals.org). We found no evidence of heterogeneity when comparing studies that used different measures of disease associations, such as risk ratio, hazard ratio, or odds ratio (Supplement Figure 6 , available at Annals.org).
DISCUSSION
Our review of 52 studies involving more than 100 000 living kidney donors found that donors had higher diastolic blood pressure, poorer renal function, and higher risk for ESRD than nondonors. Female donors also had higher risk for pregnancy-related complications, such as preeclampsia. We found no evidence that living kidney donors had higher risk for mortality, cardiovascular disease, or type 2 diabetes or reduced quality of life.
Previous systematic reviews and meta-analyses (identified through an English-language search of PubMed and Embase up to 2017) summarized data from fewer studies and reported on a limited number of outcomes, such as renal function, blood pressure, and hypertension (3, 8, 9) . The current review supports and extends earlier findings in several ways. First, we found that living kidney donors had an even greater reduction in estimated glomerular filtration rate than previously reported (3, 9) . We quantified the relative and absolute risk for ESRD and found that although the RR for ESRD was higher by about 9-fold, the absolute risk for ESRD was low, with an estimated incidence rate of less than 1 case per 1000 person-years. Second, our results on blood pressure and hypertension differed somewhat from those of a prior review (8) . Although diastolic blood pressure was higher in donors than control participants, primary analyses restricted to more recent and better-quality studies found no increase in systolic blood pressure or risk for hypertension. This could be due to more extensive follow-up and health monitoring of donors in more recent studies and better management of blood pressure (34). Our results might also be explained by better selection and matching of donor and control groups in studies included in the primary analyses.
Third, we found an almost 2-fold higher risk for pregnancy-related complications in living kidney donors than control participants, with preeclampsia twice as frequent in donors as in controls (6% vs. 3% of pregnancies). This increased risk could be due to higher blood pressure and levels of urine protein, which may lead to increased diagnosis of preeclampsia among donors (35).
Fourth, our study found no evidence of higher risk for all-cause mortality or for several chronic diseases (such as cardiovascular disease, type 2 diabetes, and cancer) in living kidney donors. Donors also had similar HRQoL to controls, which could be partially due to an increased health care-seeking behavior in living kidney donors, who are advised to follow up regularly with health care providers after nephrectomy (36). A higher frequency of health care consultations may also increase the likelihood of early diagnosis and treatment Figure 2 (available at Annals.org). † This value (also known as the Cohen D statistic) was pooled across studies with baseline recruitment ending after 2000 and a Newcastle-Ottawa Scale score ≥4 using the profile likelihood meta-analysis method.
of such conditions as hypertension and ESRD, improving the overall survival rate. However, only 1 study attempted to account for this by matching donors to control participants on the basis of frequency of nonphysician health care visits (26) . Several strengths and limitations merit careful consideration. To our knowledge, our review is the first quantitative assessment of a wide range of health outcomes among living kidney donors and adds substantial new data to previously published reviews (3, 8, 9) . We report on both relative and absolute measures of risk to better reflect the potential implications of living kidney donation on incidence of these disease outcomes. We restricted our primary analysis to higherquality and more recent studies to improve the relevance and generalizability of our findings. However, interpretability of findings is still limited by selection of the control groups in many studies. Indeed, selection of controls that do not reflect the excellent health status and careful screening of living kidney donors is a major limitation of studies assessing donors' health outcomes (4, 37, 38). We were not able to control for more intense medical surveillance of donors compared with the general population, which could have led to an increased likelihood of disease diagnosis and overestimation of disease risk (36). The follow-up duration for assessing chronic disease and mortality outcomes may have been inadequate; most studies reporting those outcomes had an average follow-up between 5 and 10 years. Few studies were from low-and middle-income countries, including those with high rates of livingdonor kidney transplantations, such as India and Brazil (1). We were also limited in our ability to assess risk for hypertension and ESRD among nonwhite donors (1, 39) and in populations with higher genetic risk, such as APOL1 carriers (39, 40). We could not assess the risk for gout and kidney stones in living kidney donors because only 1 study reported on each outcome (41, 42). These studies reported a modest increase in risk for gout and no difference in risk for kidney stones in donors compared with control participants.
Findings from this review may have implications for policies and practices related to living kidney donation. For example, donors should be informed that, although nephrectomy is associated with a higher RR for ESRD, the absolute risk is still low for most donors (that is, those not from known high-risk populations [39] ). Thus, risk prediction tools for ESRD may better approximate the risks involved for prospective donors (43). Guidelines that do not contain information about pregnancy for living kidney donors should instead include relevant information for women of childbearing age in the informed consent process. Furthermore, this review supports the need for long-term follow-up of donors to monitor their health and mitigate possible increases in disease risks associated with kidney donation (44).
In conclusion, compared with nondonor populations, living kidney donors have no increased risk for several major chronic diseases, with the exception of ESRD. However, the absolute risk for this disease remains low. Female donors who become pregnant after nephrectomy also seem to be at increased risk for preeclampsia, but more data are needed to confirm this finding. 
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